Cullinan Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.75 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | $-0.77 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-1.07 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | $-0.73 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.69 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Press releases
Announcements Cullinan Therapeutics filed with the SEC
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67 th ASH Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
T Cell Engagers in Autoimmune Diseases
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
June 2025 Cullinan Therapeutics Licensing of velinotamig (BCMAxCD3) from Genrix Bio Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CLN-978 CD19xCD3 T cell Engager
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CLN-619 and Zipalertinib Updates at ASCO June 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CLN-978 CD19xCD3 T cell Engager
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Cullinan Oncology Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K